Clincosm LogoSign in Get a demo

TOGAR: A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer

Sponsor
Baylor College of Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05567835
Collaborator
(none)
50
Enrollment
4
Locations
2
Arms
72
Anticipated Duration (Months)
12.5
Patients Per Site
0.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a randomized pilot study to evaluate and to compare the completion rates of Total Neoadjuvant chemotherapy with FLOT ( FLOT-TNT) and perioperative chemotherapy with FLOT ( FLOT-POP).

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Participants will be randomized 1:1 to either total Neoadjuvant chemotherapy with with FLOT-TNT ( all 4 cycles of chemotherapy before surgery) or standard of care FLOT-POP ( 2 cycles of chemotherapy before surgery and 2 cycles of chemotherapy after surgery). Each cycle of chemo is 28 days long with chemo administered on Days 1 and Day 15 of the cycle.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This study is a two arm phase II pilot design, with eligible subjects randomized 1:1 to either Arm A ( Investigational arm) or Arm B ( Standard arm). The chemotherapy dose modification will follow routine clinical care. Both arms will receive chemotherapy and curative surgery.This study is a two arm phase II pilot design, with eligible subjects randomized 1:1 to either Arm A ( Investigational arm) or Arm B ( Standard arm). The chemotherapy dose modification will follow routine clinical care. Both arms will receive chemotherapy and curative surgery.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized, Open Labeled Phase II Pilot Study of Total Neoadjuvant Chemotherapy With FLOT ( FLOT-TNT) VS Standard Perioperative FLOT ( FLOTPOP) in Patients With Gastric or GEJ Cancer, and Assessment of CTDNA as Correlative Biological Response
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2028
Anticipated Study Completion Date :
Jan 1, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm A: FLOT-TNT ( Investigational Arm)

Arm A is the investigational arm with all 4 cycles of FLOT given as total neoadjuvant chemotherapy prior to surgery. Each cycle is 28 days and consists of 2 chemotherapy sessions given every 14 days. The total number of chemotherapy sessions in Arm A is 8. Every effort will be made to have surgery in week 20 ( -1 to +2 weeks), 4 weeks post C4 on arm A.

Drug: Fluorouracil
2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
Other Names:
  • 5-FU

    • Drug: Leucovorin
    200 mg mg/m2 IV over 2 hours Day 1,15
    Other Names:
  • LV

    • Drug: Oxaliplatin
    85 mg/m2 IV over 2 hours Day 1,15
    Other Names:
  • Eloxatin

    • Drug: Docetaxel
    60 mg/m2 IV over 60 minutes Day 1,15
    Other Names:
  • Taxotere

    • Biological: GSCF
    Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16
    Experimental: Arm B: FLOT-POP ( Standard Arm)

    Arm B us the standard perioperative arm with 2 cycles of pre-operative FLOT ( 4 treatment sessions) and 2 cycles ( 4 treatment sessions) of post-operative FLOT. Post-surgery FLOT will start 4-6 weeks post surgery. Each cycle of chemotherapy consists of 28 days and consists of 2 chemotherapy sessions given every 14 days. The total number of chemotherapy sessions in arm B is 8. Every effort should be done to have surgery done in week 12 ( -1 to +2 weeks) post completion of cycle 2 on ARM B.

    Drug: Fluorouracil
    2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
    Other Names:
  • 5-FU

    • Drug: Leucovorin
    200 mg mg/m2 IV over 2 hours Day 1,15
    Other Names:
  • LV

    • Drug: Oxaliplatin
    85 mg/m2 IV over 2 hours Day 1,15
    Other Names:
  • Eloxatin

    • Drug: Docetaxel
    60 mg/m2 IV over 60 minutes Day 1,15
    Other Names:
  • Taxotere

    • Biological: GSCF
    Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16

    Outcome Measures

    Primary Outcome Measures

    1. Completion rate of Participants who have completed their all-allocated treatments, either Arm A: FLOT-TNT or Arm B: FLOT-POP [at week 16 for Arm A and at week 24 for Arm B]

      ArmA has all 4 cycles of FLOT given prior to surgery and ArmB has 2 cycles of pre-operative FLOT and 2 cycles of post-operative FLOT. Each cycle consists of 28 days and consists of 2 chemotherapy sessions given every 14 days. The completion rate of participants is presented based on the number of participants who have completed all treatments by their arms.

    Secondary Outcome Measures

    1. Pathologic response rate [at week 12 for Arm A and at week 20 for Arm B]

      The pathological response will be evaluated by using Mandard tumor regression grade (TRG) in the primary tumor. Mandard TRG score is from TRG0 (complete response), TRG1 (near-complete response), TRG2 (partial response), and TRG3 (poor or no response).

    2. Number of positive lymph nodes [at week 12 for Arm A and at week 20 for Arm B]

      Nodal status is assessed as positive or negative on pathology. The number of positive lymph nodes is obtained from post gastrectomy surgical specimens.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Must provide written informed consent.

    2. Must be ≥18 years of age.

    3. Must have life expectancy of greater than 3 months.

    4. Must have pathologically proven GEJ or gastric adenocarcinoma from the main tumor or local lymph nodes (pre-neoadjuvant chemo). FFPE tumor tissue from the diagnostic biopsy must be available for submission to Natera, Inc.

    5. Stage cT2 or higher, any N and M0, are eligible for the study.

    6. M0 disease must be established by both negative distant metastatic disease on imaging AND negative diagnostic laparoscopic assisted cytology of peritoneal fluid cytology not more than 28 days before registration.

    7. Must be a candidate for neoadjuvant chemotherapy.

    8. Must be a candidate for curative surgical approach.

    9. Must have an ECOG performance status 0-2.

    10. Male or female subjects of childbearing potential must be willing to use contraceptive precautions throughout the trial and for 3 months after discontinuation of study treatment. Female subjects of childbearing potential must have a negative pregnancy test within 28 days of registration. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential.

    11. Must have adequate kidney, liver, and bone marrow function, within 28 days prior to registration, as follows:

    1. Hemoglobin ≥ 8.0 gm/dL (PRBC transfusion is allowed to meet this criteria) ii. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3 iii. Platelet count ≥ 100,000 /mm3 iv. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) v. AST (SGOT) and ALT (SGPT) ≤ 3.0 times the ULN vi. Patient must have adequate renal function as evidenced by one of the following: Serum creatinine ≤ IULN OR calculated creatinine clearance ≥ 60 mL/min. This serum creatinine result must be obtained within 28 days prior to registration.

    Calculated creatinine clearance = (140 - age) x wt* (kg) x 0.85 (if female) /72 Creatinine** (mg/dl) *The kilogram weight is the subject's actual body weight with an upper limit of 140% of the IBW.

    ** Actual lab serum creatinine value with a minimum of 0.8 mg/dL l. Subjects who have required a short course urgent single modality non curative radiation treatment or gastric artery embolization for the purpose of tumor bleeding control are eligible.

    Exclusion Criteria:

    1. Positive cytology for metastatic disease on diagnostic laparoscopy peritoneal fluid. Reports such as: "cannot rule out malignancy" or "suspicious for malignancy, but not definitive" will exclude the subject from enrolling.

    2. Subjects with clinical evidence of metastatic disease.

    3. Biopsy proven metastatic disease (excluding regional lymph nodes)

    4. Prior chemotherapy for gastric or GEJ cancer

    5. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, current non-advanced prostate cancer per the discretion of the investigator, and any other cancers from which the patient has been disease free for two years.

    6. Female subjects who are pregnant, breast feeding, or of childbearing potential with a positive pregnancy test prior to baseline. Women of childbearing potential must have a negative serum pregnancy test as a part of eligibility within 28 days of registration. A persistent positive or elevated urine or blood Beta HCG test may be contributed to the primary diagnosis of GC or GEJ cancer after ruling out ectopic and intrauterine pregnancy and germ cell tumors.

    7. Subjects unwilling or unable to comply with the protocol or provide written informed consent.

    8. Any medical condition that, in the opinion of the investigator, would exclude the subject from participating in this study and treatment plan.

    9. ECOG > 2

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Baylor College of Medicine Medical Center - McNair Campus Houston Texas United States 77030
    2 Baylor College of Medicine Houston Texas United States 77030
    3 Baylor St. Luke's Medical Center Houston Texas United States 77030
    4 Harris Health System- Smith Clinic Houston Texas United States 77030

    Sponsors and Collaborators

    • Baylor College of Medicine

    Investigators

    • Principal Investigator: Tannaz Armaghany, MD, Baylor College of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Tannaz Armaghnay, Assistant Professor, Baylor College of Medicine
    ClinicalTrials.gov Identifier:
    NCT05567835
    Other Study ID Numbers:
    • H-50068
    First Posted:
    Oct 5, 2022
    Last Update Posted:
    Nov 15, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Tannaz Armaghnay, Assistant Professor, Baylor College of Medicine
    Gastric cancer
    GEJ cancer
    Additional relevant MeSH terms:
    Adenocarcinoma
    Leucovorin
    Docetaxel
    Fluorouracil
    Oxaliplatin

    Study Results

    No Results Posted as of Nov 15, 2022